Ammerschläger Hermann, Klein Peter, Weiser Michael, Oberbaum Menachem
Facharzt für Allgemeinmedizin, Aschaffenburg, Deutschland.
Forsch Komplementarmed Klass Naturheilkd. 2005 Feb;12(1):24-31. doi: 10.1159/000082934.
The primary objective of treatment of inflammatory diseases of the upper respiratory tract (rhinitis, uncomplicated sinusitis) with local decongestants is to relieve obstruction and to improve associated symptoms. Restoration of unrestricted respiration and drainage of the nasal sinuses reduce the risk of further complications (i.e. chronicity).
To determine whether the therapeutic effects of the homeopathic complex remedy Euphorbium compositum nasal drops SN are comparable to those of xylometazoline with respect to efficacy and tolerability.
Open, multicenter, prospective, active-controlled cohort study in patients with inflammatory processes and diseases of the upper respiratory tract. The primary outcome was to demonstrate non-inferiority of the homeopathic complex remedy to xylometazoline.
Clinically relevant reductions in the intensities of disease-specific symptoms were observed with both therapies. Non-inferiority of the homeopathic complex remedy to xylometazoline could be shown for all studied variables and in no case did the lower boundary of the 95% confidence interval cross the threshold of 0.5 score points. Tolerability was good with for both therapies.
This cohort study indicates a comparable efficacy and tolerability profile of the homeopathic complex remedy Euphorbium compositum nasal drops SN and the reference substance xylometazoline in patients with inflammatory processes and diseases of the upper respiratory tract.
使用局部减充血剂治疗上呼吸道炎症性疾病(鼻炎、单纯性鼻窦炎)的主要目的是缓解阻塞并改善相关症状。恢复不受限制的呼吸和鼻窦引流可降低进一步并发症(即慢性化)的风险。
确定顺势疗法复方药物大戟复方滴鼻剂SN在疗效和耐受性方面的治疗效果是否与赛洛唑啉相当。
对患有上呼吸道炎症性疾病的患者进行开放、多中心、前瞻性、活性对照队列研究。主要结果是证明顺势疗法复方药物不劣于赛洛唑啉。
两种疗法均观察到疾病特异性症状强度有临床相关的降低。对于所有研究变量,均可证明顺势疗法复方药物不劣于赛洛唑啉,并且在任何情况下,95%置信区间的下限均未超过0.5分的阈值。两种疗法的耐受性均良好。
这项队列研究表明,顺势疗法复方药物大戟复方滴鼻剂SN与对照物质赛洛唑啉在上呼吸道炎症性疾病患者中具有相当的疗效和耐受性。